Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Viralytics targets cash injection for cancer research

The halt will remain in place until Monday 8th January 2018.
Viralytics targets cash injection for cancer research
The company's shares are in pre-open

Viralytics' (ASX:VLA) lead drug CAVATAK® harnesses the common cold virus to infect and kill cancer cells, with a market-leading body of clinical evidence across multiple cancer indications.

A global opportunity is currently being unlocked via a combination with leading in-market immunotherapies (KEYTRUDA® and YERVOY®) creating a clear path to market in area of high unmet need.

To advance the next steps, Viralytics is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.

The halt will remain in place until the opening of trade on Monday 8th January 2018, or earlier if an announcement is made to the market.

View full VLA profile View Profile

Viralytics Timeline

December 10 2015

Related Articles

June 21 2018
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
man and woman working in a lab
October 11 2018
There were no adverse safety findings and excellent drug-like properties were confirmed.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use